New class of drugs to treat blood and bone marrow cancers: ResearchhealthUpdated: Dec 26, 2020, 17:04 ISTA group of scientists in the US, including an Indian-American from the prestigious Cleveland Clinic, have identified a potential new class of drugs that may prove effective in treating certain common types of blood and bone marrow cancers. Myeloid leukemias are cancers derived from stem and progenitor cells in the bone marrow that give rise to all normal blood cells. While all members of the TET family are dioxygenases, the most powerful enzymatic activity belongs to TET2, the press release said. Even when TET2 is mutated, however, its related genes TET1 and TET3 provide residual enzymatic activity. Cleveland Clinic said that the researchers studied TETi76’s effects in both preclinical disease and xenograft models (where human cancer cells are implanted into preclinical models).

Source: Hindustan Times December 26, 2020 11:35 UTC